Industry Research

The data shown on this page comes from Industry Standard Research (ISR), a full-service market research provider to the pharma and pharma services industries.

  • Trends In Phase 4 CRO Selection Drivers
    Trends In Phase 4 CRO Selection Drivers

    As part of our yearly service provider quality benchmarking, Industry Standard Research asks late-phase decision makers to select their top five most important attributes when outsourcing with no preferred providers.

  • Outsourcing Motivations Should Guide One’s Outsourcing Approach
    Outsourcing Motivations Should Guide One’s Outsourcing Approach

    Outsourcing motivations are important considerations to identifying the best outsourcing approach and should influence the type of relationships your organization develops with CMOs. Data comes from ISR’s CMO Quality Benchmarking suite of market research reports and ISR’s Development and Commercial Outsourcing Models market research report.

  • Influence Of Size In CRO Selection
    Influence Of Size In CRO Selection

    ISR surveyed hundreds of clinical development outsourcers about what they consider important when selecting providers. To capture the increasing role that preferred provider agreements are playing in the selection process, respondents were asked about attribute importance in several scenarios.

  • How Prevalent Are PPAs In Phase 2/3 Research?
    How Prevalent Are PPAs In Phase 2/3 Research?

    Almost half of survey respondents report their companies use formal preferred provider agreements (PPAs) for their Phase 2/3 outsourcing.

  • Are Outsourcers Interested In Changing Their CRO Mix?
    Are Outsourcers Interested In Changing Their CRO Mix?

    ISR recently surveyed decision makers across all phases of clinical development to gain insight on sponsor/CRO dynamics. More than half of respondents agreed (to some level)that their organization would change its mix of CROs.

  • A Look At 2018’s CDMO Expansions
    A Look At 2018’s CDMO Expansions

    ISR looked at each month in the past year to identify the biggest expansion news announced by large CDMOs.

  • Decision-making Responsibilities When Outsourcing Late-Phase Studies
    Decision-making Responsibilities When Outsourcing Late-Phase Studies

    A look at which departments at sponsor organizations are involved in the decision-making process and how much decision-making responsibility each department has for outsourcing various late-phase study activities.

  • The Interconnected World Of Blockbuster Oncology Drugs
    The Interconnected World Of Blockbuster Oncology Drugs

    A hypertree showing the network of connections between 2017’s top-selling oncology products. Oncology drugs made up 13 of last year’s top 50 selling products.

  • The Top 5 Selection Drivers For Phase IV Services
    The Top 5 Selection Drivers For Phase IV Services

    Understanding which attributes industry peers feel are important can help in the process of CRO selection.

  • Department Influence On CMO Selection
    Department Influence On CMO Selection

    When it comes to CMO selection, Executive Management and Manufacturing/Production hold the most influence over the decision, each accounting for ~20% of control.

  • Choosing A Development-Stage eCOA/ePRO Provider
    Choosing A Development-Stage eCOA/ePRO Provider

    ISR asked study sponsors, CROs, and clinical research sites what’s the most important attribute they would use to select an eCOA (electronic clinical outcomes assessment)/ePRO (electronic patient reported outcomes) provider for development-stage products.

  • What Are The Largest Slices Of The 2018 CRO Market?
    What Are The Largest Slices Of The 2018 CRO Market?

    2017 was another strong year for CRO growth, with all major/public service providers experiencing year-over-year revenue gains. The largest component of CRO market revenue by geography, development, and service line is highlighted here.

  • Is The U.S. Biosimilar Industry Falling Behind?
    Is The U.S. Biosimilar Industry Falling Behind?

    Eighty-seven percent of global biosimilar sales come from the E.U., compared to just 2 percent from the U.S. We asked outsourced biomanufacturing decision-makers from North America and Europe to share their companies’ stances on selling and manufacturing biosimilars.

  • Trial Data Collection: Paper Vs. Electronic
    Trial Data Collection: Paper Vs. Electronic

    The use of electronic data collection tools is prevalent across clinical trial phases. Respondents with visibility into Phase 4 studies report 90 to 96% of these studies use electronic data capture tools, either exclusively or as part of a hybrid EDC/paper strategy.

  • 10 Years Of CRO Performance
    10 Years Of CRO Performance

    The 10th Edition of ISR’s CRO Quality Benchmarking Suite comes out this year. Here we take a look at how the CRO landscape has changed throughout the past decade.

  • The Evolution Of IRT
    The Evolution Of IRT

    Integration with eClinical software applications will drive IRT (interactive response technology) enhancements, but it is important to many study sponsors that IRT be delivered though companies that specialize in this technology.

  • 2018 NDAs: Living In The Wake Of 2017
    2018 NDAs: Living In The Wake Of 2017

    What is the effect of a near-record volume of drug approvals? Just think about the potential impact on manufacturing, market access, late-phase clinical development, and sales and marketing activities.

  • What Drives CRO Preferred Provider Selection?
    What Drives CRO Preferred Provider Selection?

    Using data from several market research reports, Industry Standard Research analyzed preferred provider arrangements across clinical development, eClinical, and contract manufacturing industries. Go to ISRreports.com/free-industry-resources to see the full infographic, which includes data for the contract manufacturing and eClinical markets.

  • Experiential Data Sheds Light On The CRO Selection Process
    Experiential Data Sheds Light On The CRO Selection Process

    Industry Standard Research (ISR), a full-service market research provider to the pharma and pharma services industries, has collected information from outsourcing decision makers via an online survey regarding their selection and evaluation of CROs.

  • Pharma Industry Lacks Consensus On Key Attribute Of A Sponsor-CMO Relationship
    Pharma Industry Lacks Consensus On Key Attribute Of A Sponsor-CMO Relationship

    Over the past several decades, the practice of outsourcing has evolved from transactional, client-vendor relationships where cost savings were the primary focus, to preferred provider relationships with pre-vetted companies to start up projects quickly and then to relationships more strategic in nature to gain access to technologies, skills, or expertise not possessed in-house.

More From Industry Research

BEYOND THE PRINTED PAGE

More From Beyond The Printed Page

LIFE SCIENCE LEADER BLOGS

  • What’s It Like To Be A Panelist At BIO?
    What’s It Like To Be A Panelist At BIO?

    Chris Anselmo provides his thoughts as a first time panelist and attendee of the 2019 BIO International Convention and Conference, Philadelphia, PA, June 3 - 6.

  • BIO And JPM — So Much In Common, And Yet So Different
    BIO And JPM — So Much In Common, And Yet So Different

    While the annual BIO International Convention and Conference has much in common with the annual J.P. Morgan Healthcare Conference, first time attendee of BIO, Matt Pillar, quickly picks up on key points of differentiation at BIO 2019 this year in Philadelphia, PA, June 3 - 6.

More From Life Science Leader Blogs

@LIFESCIENCELEADER1